Prestige Consumer Healthcare (NYSE:PBH) Reaches New 12-Month High Following Better-Than-Expected Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) shares reached a new 52-week high during mid-day trading on Friday following a stronger than expected earnings report. The stock traded as high as $87.39 and last traded at $87.21, with a volume of 768028 shares traded. The stock had previously closed at $76.10.

The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%.

Analyst Ratings Changes

A number of research firms have recently commented on PBH. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research report on Monday, December 9th. DA Davidson reaffirmed a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Finally, StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Insider Activity at Prestige Consumer Healthcare

In related news, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its stake in Prestige Consumer Healthcare by 3.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock valued at $126,274,000 after purchasing an additional 49,331 shares in the last quarter. Geode Capital Management LLC grew its stake in Prestige Consumer Healthcare by 4.0% in the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares in the last quarter. Congress Asset Management Co. grew its stake in Prestige Consumer Healthcare by 5.0% in the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock valued at $70,964,000 after purchasing an additional 43,619 shares in the last quarter. Boston Trust Walden Corp grew its stake in Prestige Consumer Healthcare by 43.5% in the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after purchasing an additional 252,089 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Prestige Consumer Healthcare by 5.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock valued at $49,667,000 after purchasing an additional 33,844 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Price Performance

The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The company has a 50 day moving average price of $79.13 and a 200 day moving average price of $75.26. The company has a market capitalization of $4.31 billion, a P/E ratio of 21.22, a P/E/G ratio of 2.15 and a beta of 0.50.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.